Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Inv. presentation Appointed director
|
CHINA JO-JO DRUGSTORES, INC. (CJJD)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
07/30/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
07/29/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
07/28/2021 |
8-K
| Quarterly results |
07/20/2021 |
8-K
| Submission of Matters to a Vote of Security Holders |
07/01/2021 |
8-K
| Quarterly results |
06/29/2021 |
10-K
| Annual Report for the period ended March 31, 2021 |
06/02/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
05/14/2021 |
8-K
| Quarterly results |
04/22/2021 |
8-K
| Quarterly results |
02/12/2021 |
8-K
| Quarterly results |
02/12/2021 |
10-Q
| Quarterly Report for the period ended December 31, 2020 |
12/23/2020 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
11/24/2020 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
11/13/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
11/13/2020 |
8-K
| Quarterly results
Docs:
|
"China Jo-Jo Drugstores Reports Second Quarter 2021 Financial Results HANGZHOU, China, November 13, 2020 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. , a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced its financial results for the second fiscal quarter ended September 30, 2020. Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, “We are pleased with our second quarter performance as we delivered another quarter of strong results. Our revenue and gross profit recorded $30.84 million and $7.01 million for the second fiscal quarter of 2021, up 8.8% and 4.8% compared to same period of fiscal year 2020. Revenue year-over-year from online pharmacy increased by 127.4%. We have al..." |
|
10/29/2020 |
8-K
| Submission of Matters to a Vote of Security Holders |
10/22/2020 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
09/14/2020 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
08/25/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
08/14/2020 |
10-Q
| Quarterly Report for the period ended June 30, 2020 |
08/14/2020 |
8-K
| Quarterly results |
07/14/2020 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
07/10/2020 |
10-K
| Annual Report for the period ended March 31, 2020 |
07/10/2020 |
8-K
| Quarterly results |
06/26/2020 |
8-K
| Other Events |
06/15/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/03/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits
Docs:
|
"China Jo-Jo Drugstores Announces the Closing of $10 Million Registered Direct Offering HANGZHOU, China, June 3, 2020 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. , a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that it closed its previously announced registered direct offering with certain institutional investors for an aggregate of 5,000,004 shares of the common stock, at a purchase price of $2.00 per share, for aggregate gross proceeds of approximately $10 million to the Company. In a concurrent private placement, the Company issued to the same investors unregistered warrants to purchase up to an aggregate of 3,750,003 shares of the common stock at an exercise price of $2.60 pe..." |
|
06/02/2020 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
06/02/2020 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
03/09/2020 |
8-K
| Quarterly results |
02/14/2020 |
10-Q
| Quarterly Report for the period ended December 31, 2019 |
02/14/2020 |
8-K
| Quarterly results |
01/21/2020 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
01/08/2020 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 4.9% stake in China Jo-Jo Drugstores, Inc. |
|
|
|